


# Contents

1	<b>Summary, 1</b>
	Summary of Findings, 1
	Introduction, 3
	Origins and Scope of OTA's Study, 3
	Issues Beyond the Scope of This Study, 4
	The Nature of Pharmaceutical R&D Investments, 4
	R&D Costs: The Evidence, 10
	Returns on R&D: The Evidence, 19
	Total Pharmaceutical Industry Returns, 23
	Industry Response: Increasing R&D, 24
	Payment Policy and Returns on R&D, 26
	The Regulation of Pharmaceutical R&D, 32
	Federal Tax Policies Affecting Pharmaceutical R&D, 33
	Federal Support for Pharmaceutical R&D, 34
2	<b>Research and Development Expenditures, 39</b>
	How to Measure R&D Spending, 39
	Trends in Domestic R&D Spending, 42
	Trends in Worldwide Pharmaceutical R&D Expenditures, 43
	Directions of Pharmaceutical R&D, 44
	Interpreting Aggregate Trends, 46
3	<b>The Costs of Pharmaceutical R&amp;D, 47</b>
	A Framework for Estimating R&D Costs, 47
	Existing Studies of R&D Costs, 48
	Validity of R&D Costs Estimates, 54
	Other Factors Affecting Validity, 66
	Tax Savings From R&D, 67
	Recent Trends in the Cost of R&D, 69
	Conclusions, 72



#### **4 Returns on Pharmaceutical R&D, 73**

- Returns on R&D: The Evidence, 76
- Total Pharmaceutical Industry Returns, 95
- Findings and Conclusions, 104

#### **5 Trends in Science, Technology and Drug Discovery, 105**

- Drugs and Receptors, 106
- Protein Analysis and Proteins as Pharmaceutical Agents, 113
- Genetics in Biomedical Research, 119
- DNA as a Therapeutic Agent, 127
- Discovery Increasingly Driven by Biomedical Research, 131
- Implications for Future Pharmaceutical R&D Cost, 132

#### **6 Government Regulation and Pharmaceutical R&D, 135**

- The Impact of Pharmaceutical Regulation on R&D Costs and Output, 136
- The U.S. Regulatory Review Process for New Drugs, 138
- Efforts to Expedite FDA New Product Regulations, 151
- Trends in the R&D and Regulatory Review Processes, 158
- Trends in the Regulation of Pharmaceuticals in Other Countries, 163
- Conclusions, 167

#### **7 Product Liability and the Pharmaceutical Industry, 169**

- Product Liability and Pharmaceutical R&D, 169
- Pharmaceuticals and Product Liability Law, 170
- Product Liability Insurance, 172
- Product Liability Claims and R&D, 173
- Government Policy and product Liability, 180
- Conclusions, 182

## **8 Federal Tax Policy and Drug Research and Development, 183**

- Analyzing Tax Policy, 183
- Tax Deductions and Taxable Income, 184
- Tax Credits, 186
- Other Nations' R&D Tax Incentives, 197
- Conclusions, 198

## **9 Federal Support for Pharmaceutical Research and Development, 201**

- Federal Support for Life Sciences, 203
- Collaboration Between Pharmaceutical Firms and Academia, 206
- Targeted Federal Pharmaceutical R&D Programs, 210
- Industry Collaboration With Federal Research Laboratories, 217
- Orphan Drugs, 225
- Medicare and Medicaid Support for Clinical Drug R&D, 232
- Conclusions, 233

## **10 Trends in Payment for Prescription Drugs, 237**

- Health Insurance for Prescription Drugs in the United States, 238
- Prescription Drug Benefits in Other Countries, 250
- Conclusions, 262

## **APPENDIXES**

**A Method of Study, 265**

**B Acknowledgments, 269**

**C The Cost of Capital, 276**

**D Congressional Access to Proprietary Pharmaceutical Industry Data, 284**

- E Patent Protection of Pharmaceuticals in the United States, 290
- F Summary of Methods Used to Analyze Trends in Postpatent Revenues, 294
- G Estimating the Cost of Producing and Selling New Chemical Entities, 302
- H Methods of OTA's Survey of Clinical Trial Size, 308
- I Methods Used in OTA's Study of Success Rates for New Molecular Entities, 309
- J Estimates by OTA and JCT of Federal Tax Credits Attributable to Pharmaceuticals, 310
- K Federal Programs Dedicated to Pharmaceutical R&D, 311
- L Acronyms and Glossary of Terms, 316

**REFERENCES, 323**

**INDEX, 347**